Pfizer CEO Albert Bourla announced the acquisition of Metsera for $10 billion, emphasizing the company’s focus on the obesity drug market. Novo Nordisk, a competitor, had bid for Metsera, prompting Pfizer to double its offer to secure the deal.

Pfizer’s stock remained steady post-announcement but has since risen by approximately 4.9%. Metsera’s monthly GLP-1 injection is seen as a market-leading product that Pfizer is well-equipped to bring to market due to its expertise in large-scale trials and manufacturing.

Pfizer aims to launch Metsera’s new GLP-1 products by 2028. The company faced an activist campaign earlier in 2025 but successfully navigated through it. In a strategic move, Pfizer agreed to lower drug prices and participate in the Trump administration’s plan to allow customers to buy drugs directly from manufacturers at discounted rates.

Despite challenges, Pfizer remains confident in its position in the healthcare sector, particularly in oncology, obesity, and vaccines. CEO Bourla highlighted the company’s independence from China in terms of product manufacturing and its commitment to leading the way in key healthcare areas.

Read more at Yahoo Finance: Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company’s ‘right to win’ obesity market